Lacosamide Arrow (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing these channels, it reduces the ability of neurons to fire repetitively, thereby limiting the spread of epileptic activity without significantly affecting normal neuronal signaling.

The specific dosing regimen for Lacosamide Arrow is determined by the prescribing clinician based on the patient’s condition, age, weight, renal and hepatic function, and concomitant therapies. Healthcare professionals set the appropriate dose and infusion rate for each individual case.

The safety of lacosamide during pregnancy and lactation has not been fully established. Clinicians should evaluate the potential benefits against possible risks to the fetus or infant, and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and required import documentation.

Lacosamide offers a unique mechanism by selectively enhancing slow sodium‑channel inactivation, which can provide seizure control with a different side‑effect profile compared with traditional sodium‑channel blockers such as carbamazepine. Its intravenous formulation allows rapid administration in emergency settings, a feature not shared by many oral antiepileptics.

Lacosamide Arrow should be stored at 2‑8 °C in a refrigerator, protected from light. The solution must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability and sterility.

The product is supplied as a sterile intravenous solution. It is administered by slow infusion through a suitable IV line, following the infusion rate and duration prescribed by the treating physician. Proper aseptic technique and infusion set compatibility should be observed.

Serious adverse events include cardiac arrhythmias such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, and respiratory depression. Patients should be monitored for cardiac conduction changes and any signs of hypersensitivity during and after infusion.

Lacosamide Arrow is contraindicated in patients with known hypersensitivity to lacosamide or any component of the formulation. Caution is also advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or those receiving strong enzyme‑inducing antiepileptic drugs that may markedly reduce its effectiveness.